FDA Guidance Could Impose Drug-Like Burden On Cosmetic Trials
This article was originally published in The Rose Sheet
Executive Summary
An FDA guidance document intended to clarify if firms conducting certain drug studies involving human subjects are obligated to file Investigational New Drug Applications instead raises questions for the cosmetics industry.